Article in The Journal of infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
11 authors.
Maribeth R NicholsonDivision of Pediatric Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.ORCID 0000-0003-3941-5599
Siyuan MaDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Britton A StricklandDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Mia CecalaDivision of Pediatric Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Lisa ZhangDivision of Pediatric Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Seth ReasonerDivision of Molecular Pathogenesis, Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.ORCID 0000-0002-7791-1641
Emma R GuibersonDepartment of Chemistry, Middlebury College, Middlebury, Vermont, USA.ORCID 0000-0002-1579-7820
Matthew J MunnekeDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Meghan H ShiltsDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.ORCID 0000-0002-3879-6070
Eric P SkaarDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.ORCID 0000-0001-5094-8105
Suman R DasDepartment of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Funding
Tumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Ben Ho Park · 1995 to 2026
$172.8M
Vanderbilt Institute for Clinical and Translational Research (VICTR) -Identifying correlates of functional immunity in SARS-CoV-2 convalescent plasmaUL1TR002243 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Paul A. Harris, Wesley H Self · 2017 to 2026
$130.7M
VANDERBILT UNIVERSITY CTSA FOR PEDIATRIC RESEARCHUL1RR024975 · NCRR · VANDERBILT UNIVERSITY · PI BERNARD, GORDON RAPHAEL · 2007 to 2011
$45.7M
ECHO Laboratory Core at Vanderbilt for Integrated Sample Biobanking and ProcessingU24OD035523 · OD · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Suman Ranjan Das, NATASHA Bassam HALASA · 2023 to 2026
$32.8M
Translational Analysis CoreP30DK058404 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI MARY Kay WASHINGTON · 2002 to 2026
$29.9M
Shop Module CoreP30EY008126 · NEI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI David J. Calkins · 1989 to 2026
$19.6M
VANTAGE:Consolidation to create the Vanderbilt Technologies for Advanced GenomicsG20RR030956 · NCRR · VANDERBILT UNIVERSITY · PI PIETENPOL, JENNIFER A · 2010 to 2010
$8.7M
Host-mediated zinc sequestration during Acinetobacter baumannii infectionR01AI101171 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI WALTER J. CHAZIN, DAVID P. GIEDROC · 2013 to 2026
$8.2M
Vanderbilt Antibody and Antigen Discovery for Clostridioides difficile VaccinesU19AI174999 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Maribeth Ruth Nicholson · 2023 to 2026
$7.9M
Molecular Interrogation of the Host-Pathogen Interface in Idiopathic Subglottic StensosisR01HL146401 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI GELBARD, ALEXANDER · 2019 to 2023
$1.9M
Integrated Metagenomic and Metatranscriptomic Characterization of Inflammatory Chronic Rhinosinusitis EndotypesR21AI142321 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI DAS, SUMAN RANJAN, TURNER, JUSTIN H · 2020 to 2021
$924k
Immune, Microbial, and Metabolic Factors that Impact Clostridioides difficile and Inflammatory Bowel Disease in ChildrenK23AI156132 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI NICHOLSON, MARIBETH RUTH · 2021 to 2025
$876k
Digestive Disease Research CenterNational Institute of Allergy and Infectious Diseases K23AI156132National Institute of Allergy and Infectious Diseases R21AI142321National Institute of Allergy and Infectious Diseases R21AI149262National Institute of Allergy and Infectious Diseases R21AI154016NCATS NIH HHS UL1 TR002243NCI NIH HHS P30 CA068485NCRR NIH HHS G20 RR030956NCRR NIH HHS UL1 RR024975NEI NIH HHS P30 EY008126NHLBI NIH HHS R01 HL146401NHLBI NIH HHS R01HL146401NIAID NIH HHS F31 AI172352NIAID NIH HHS K23 AI156132NIAID NIH HHS L30 AI140315NIAID NIH HHS R01 AI101171NIAID NIH HHS R21 AI142321NIAID NIH HHS R21 AI149262NIAID NIH HHS R21 AI154016NIAID NIH HHS U19 AI174999NIDDK NIH HHS P30 DK058404NIH HHS G20RR030956NIH HHS P30CA68485NIH HHS P30DK058404NIH HHS P30EY08126NIH HHS U24 OD035523NIH HHS UL1RR024975Vanderbilt University Medical Center
6 · The paper itself
Abstract
backgroundSymptomatic Clostridioides difficile infection (CDI) can cause significant morbidity and mortality. Conversely, patients can be colonized with toxigenic C. difficile in the absence of symptoms, termed asymptomatic colonization. We previously demonstrated that the presence and function of C. difficile toxins do not differentiate between asymptomatic colonization and CDI in children, suggesting the influence of other factors. This study aimed to interrogate the intestinal microbiome and butyrate in stool samples from children with CDI and asymptomatic colonization.
methodsDesign: case-control study. Setting: tertiary care children's hospital. Participants and measures: asymptomatic children had stool tested for C. difficile by nucleic-acid amplification-based testing (NAAT) and were considered colonized if positive (n = 50). Residual stool was also obtained from symptomatic children who tested positive for C. difficile by NAAT (n = 55). The microbiome was assessed via 16S rRNA sequencing and butyrate via liquid chromatography-mass spectrometry.
resultsCompared with clinical covariates and comorbidities, C. difficile symptom status (ie, asymptomatic colonization vs symptomatic CDI) demonstrated the strongest differential abundance association on gut microbes. Symptomatic CDI was associated with increased abundance of Escherichia/Shigella (Benjamini-Hochberg adjusted q = 3.94 × 10-5), Haemophilus (q = 0.022), and Gemella (q = 0.085), and depleted abundance of gut commensals such as Faecalibacterium (q = 0.041), Blautia (q = 0.041), and Bifidobacterium (q = 0.063). We also observed depletion in the abundance of microbial butyrate producers and fecal butyrate in participants with symptomatic CDI versus asymptomatic colonization.
conclusionsThe gut microbiota and butyrate differ between participants with asymptomatic C. difficile colonization and symptomatic CDI, suggesting their potential role in symptom development.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
The Gut Microbiome and Butyrate Differentiate Clostridioides difficile Colonization and Infection in Children. · full record | OpenQuestion